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In inflammation, the post-transcriptional regulation of transiently expressed genes provides a potential therapeutic target. Triste-
traprolin (TTP) is of the factors regulating decay of cytokine mRNAs. The aim of the present study was to identify cytokines whose
expression is regulated by TTP. We established a TTP knock-down cell line by expressing shRNA against TTP (shTTP cell line). A
cytokine antibody array was used to measure cytokine production in macrophages exposed to lipopolysaccharide (LPS). Cytokines
IL-6, IL-12, TNF-α, and MIP-2 (a homologue to human IL-8) were expressed at higher levels whereas MIP-3α was produced at
lower levels in LPS-treated shTTP cells than in control cells suggesting that the expression of these cytokines is regulated by TTP.
The present data provide IL-12, MIP-2, and MIP-3α as novel inflammatory cytokine targets for TTP-mediated mRNA decay and
stress the role of TTP in the regulation of the inflammatory process.
Copyright © 2006 Ulla Jalonen et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
In inflammation, the post-transcriptional regulation of tran-
siently expressed genes provides a potential therapeutic tar-
get. The regulation of mRNA stability through AU-rich el-
ement (ARE)-containing areas in the 3 -untranslated region
has been found an importantmeans to regulate cytokine pro-
duction. Tristetraprolin (TTP) is one of the factors known to
regulate mRNA stability and expression of proinflammatory
cytokines especially tumor necrosis factor (TNF)-α. TTP
(synonyms: Nup475, TIS11, G0S24, and Zfp36) expression is
induced by inflammatory and related stimuli including bac-
terial products, growth factors, 12-O-tetradecanoylphorbol-
13-acetate ester and serum [1–6]. TTP is a member of a
CCCH tandem zinc finger protein family that also contains
Zfp36-like 1, Zfp36-like 2 and the recently found Zfp36-like
3 [7, 8]. TTP has been reported to bind the ARE of certain
mRNAs, which leads to mRNA deadenylation and degrada-
tion [9, 10]. Recent articles suggest that TTP is a compo-
nent of both stress granules and processing bodies [11] and
that the zinc finger domain is needed to localize TTP into
the stress granules, which are sites of stalled translational
preinitiation complexes [12]. TTP also recruits and activates
enzymes needed in ARE-containing mRNA decay [13], and
TTP seems to have a multifunctional role in mRNA degrada-
tion.
Inflammatory tissues such as spleen, lymph nodes, and
thymus express TTP mRNA [2, 3]. The significant role of
TTP in inflammation was first discovered in TTP knock-out
mice, which developed a set of severe inflammatory symp-
toms due to high levels of TNF-α [14]. In TTP deficient ani-
mals, the levels of TNF-α were elevated because of increased
TNF-α mRNA stability [9, 15]. The mRNAs of granulo-
cyte macrophage colony stimulating factor (GM-CSF), in-
terleukin (IL)-2, IL-3, IL-6, cyclooxygenase-2 (COX-2), and
plasminogen activator inhibitor type 2 have also been re-
ported to be destabilized by TTP [16–21]. In contrast, TTP
has been shown to inhibit human inducible nitric oxide syn-
thase (iNOS) mRNA degradation. TTP did not bind to the
iNOS mRNA but its eﬀect was mediated through interac-
tion with the KH-type splicing regulatory protein (KSRP)
[22].
In the present study, we established a cell line express-
ing shRNA against TTP resulting in reduced TTP expres-
sion in response to inflammatory stimulus. In the further
studies, we used a cytokine antibody array to measure the
eﬀects of TTP down-regulation on cytokine production in
macrophages exposed to LPS.
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MATERIALS AND METHODS
Cell culture
J774 murine macrophages (American Type Culture Collec-
tion, Rockville, Md, USA) were cultured at 37ÆC in humid-
ified 5% carbon dioxide atmosphere in Dulbecco’s modified
Eagle medium with Ultraglutamine 1 (DMEM/U1, Cambrex
Bioproducts Europe, Verviers, Belgium) supplemented with
10% heat-inactivated FBS (EuroClone, Wetherby, UK), peni-
cillin (100 units/mL), streptomycin (100 μg/mL) and am-
photericin B (250 ng/mL) (Gibco, Paisley, Scotland, UK).
Cell lines expressing short hairpin RNAs (shRNA) against
TTP or a negative control sequence
The nucleotides (Table 1) (Metabion, Planegg-Martinsried,
Germany) were annealed and ligated into the pSilencer
neo vector (Ambion Inc, Austin, Tex, USA) with T4 DNA
ligase (Fermentas Inc, Burlington, Ontario, Canada). One
Shot TOP10 Competent Cells (Invitrogen, Paisley, UK) were
chemically transformed according to the manufacturer’s in-
structions. Plasmids were isolated with PlasmidMini kit (QI-
AGEN Inc, Santa Clarita, Calif, USA) and transfected with
FuGENE 6 Transfection Reagent (Roche Diagnostics Corpo-
ration, Indianapolis, Ind, USA) into J774macrophages. G418
disulfide salt (Sigma Chemical Co, St Louis, Mo, USA) was
used to select and maintain the J774 cell lines expressing
shRNA against TTP (shTTP) and negative control shRNA
(shNEG).
Stimulation of shTTP and shNEG cell lines
For the cytokine protein array, shTTP and shNEG cells were
plated on 6 well plates 24 h prior to the experiment. Cells
were first incubated in DMEM/U1 + FBS with or without
LPS (100 ng/mL) (Sigma, St Louis, Mo, USA). After 1 h of
incubation medium without FBS was changed to the wells
and incubation was continued for 48 h. Thereafter, cell cul-
ture mediums were collected and stored at  20ÆC until as-
sayed.
For Western blot shTTP and shNEG cells were plated on
6 well plates and grown to confluence. Cells were treated with
or without LPS (100 ng/mL) for 6 h and proteins were ex-
tracted as described [23].
Western blotting
The protocol for Western blotting was described in [23].
The gels were loaded with 50 μg of protein. Actin antibody
was purchased from Santa Cruz Biotechnology, Santa Cruz,
Calif, USA and the mouse TTP antibody was a kind gift from
Dr Perry Blackshear (NIEHS, Research Triangle Park, NC,
USA). The bound antibodies were detected using Super Sig-
nal West Pico (for actin) or Dura (for TTP) chemilumines-
cent substrate for HRP detection (Pierce, Cheshire, UK) and
FluorChem 8800 imaging system (Alpha Innotech, San Le-
andro, Calif, USA). The chemiluminescent signals were mea-
sured with FluorChem software v. 3.1.
TNF-α enzyme-linked immunosorbent assay (ELISA)
TNF-α concentrations in culture media were determined by
mouse TNF-α DuoSet ELISA kit (R&D Systems, Inc, Min-
neapolis, Minn, USA) according to the manufacturer’s in-
structions.
Cytokine antibody array
Cytokines were detected in cell culture media with Mouse
Cytokine Antibody Array III (RayBiotech, Inc, Norcross, Ga,
USA), which measures 62 cytokines and other inflamma-
tory mediators. The array membranes were blocked with
2mL of 1X blocking buﬀer for 30min and then incubated
with the sample (1mL) for 2 h at room temperature. The
membranes were washed three times with 2mL of 1X wash
buﬀer I and twice with 2mL of 1X wash buﬀer II at room
temperature. The membranes were then incubated in di-
luted primary antibodies over night at +4ÆC. The mem-
branes were washed as described earlier and incubated with
diluted HRP-conjugated streptavidin for 2 h at room temper-
ature and washed. Detection buﬀer C and detection buﬀer
D were combined and applied on the membranes for 2min.
Each membrane was exposed for 1min and images were
taken with FluorChem 8800 imaging system (Alpha Innotech
Corp, San Leandro, Calif, USA) and chemiluminescent sig-
nals for each spot were measured with FluorChem software
v. 3.1. The average chemiluminescence of each cytokine and
control was calculated for all the treatments separately. The
average of positive controls of each treatment was set to 100
and all cytokines of the same treatment were compared to
that.
Statistics
Results are expressed as the mean  standard error of mean
(SEM). The significance of diﬀerences was calculated by anal-
ysis of variance supported by Dunnett’s adjusted significance
levels. A diﬀerence between treatment groups was considered
significant when P < .05.
RESULTS
Down-regulation of TTP expression in macrophages
transfected with shTTP
J774 macrophages were transfected with shTTP expression
vector (shTTP cell line) or with shNEG negative control vec-
tor (shNEG cell line) and maintained under G418 disulfide
salt selection. Neither of the cell lines expressed detectable
amounts of TTP protein when cultured in the absence of
lipopolysaccharide (LPS). When LPS (100 ng/mL) was added
into the culture, TTP was clearly expressed in shNEG cell
line whereas TTP protein expression was markedly lower in
shTTP cells (Figure 1(a)).
TTP knock-out mice have been shown to have increased
levels of circulating TNF-α due to increased TNF-α mRNA
stability in the absence of TTP [15, 24]. LPS-induced TNF-
α levels produced by shNEG and shTTP cell lines were
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Table 1: Target sequences and primers of shTTP and shNEG.
shTTP target sequence 5 -AACAUAAACUCGGACUCCAUC-3 
shTTP sense 5 -GATCCGCATAAACTCGGACTCCATCTTCAAGAGAGATGGAGTCCGAGTTTATGTTTTTTGGAAA-3 
shTTP antisense 5 -AGCTTTTCCAAAAAACATAAACTCGGACTCCATCTCTCTTGAAGATGGAGTCCGAGTTTATGCG-3 
shNEG target sequence 5 -AAACUACCGUUGUUAUAGGUG-3 
shNEG sense 5 -GATCCACTACCGTTGTTATAGGTGTTCAAGAGACACCTATAACAACGGTAGTTTTTTTGGAAA-3 
shNEG antisense 5 -AGCTTTTCCAAAAAAACTACCGTTGTTATAGGTGTCTCTTGAACACCTATAACAACGGTAGTG-3 
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Figure 1: Down-regulation of TTP expression and enhancement of
TNF-α production in shTTP cells. (a) shNEG and shTTP cells were
stimulated with LPS (100 ng/mL) and proteins were extracted af-
ter 6 h of incubation. TTP and actin were detected by Western blot.
The blot is a representative of three blots with similar results. (b)
shNEG and shTTP cells were stimulated with LPS (100 ng/mL) for
1 h. Thereafter the medium was changed and the cells were incu-
bated for another 48 h. TNF-α concentrations in the culture me-
dia were measured by ELISA. Values are mean   SEM (n = 3).
 = P < .01.
determined by ELISA. The results show that the TNF-α levels
were more than three fold higher in LPS-treated shTTP cells
than in shNEG cells (Figure 1(b)) confirming the functional
consequences of TTP knock-down in shTTP cells.
Cytokine production in shNEG and shTTP cell lines
Cytokine production in shNEG and shTTP cell lines was
measured by using an antibody array that detects 62 cy-
tokines and other inflammatory mediators (Figure 2(a)).
shNEG and shTTP cell lines were incubated with or without
LPS (100 ng/mL) and cytokines produced into the culture
medium were measured after 48 h incubation. An example
membrane of each treatment is shown in Figures 2(b)–2(f).
When analyzing the results of the cytokine antibody ar-
ray the positive control was set as 100 and the cytokine results
were related to the positive control. The average of negative
controls and blanks obtain values <2.5. The immunoreactiv-
ity of diﬀerent cytokines in the cell culture medium was < 5
when compared to the positive controls.
In the absence of LPS, shNEG, and shTTP cell lines
produced five out of the 62 measured cytokines into the
culture medium, that is, cutaneous T-cell attracting che-
mokine (CTACK), CXCL16, MIP-1α, MIP-1γ and thymus
and activation-regulated chemokine (TARC). Between the
shNEG and shTTP cell lines, CXCL16 was expressed at
higher levels in shNEG cell line whereas only minor diﬀer-
ences between shNEG and shTTP cell lines were found in the
other cytokines. The results are shown in Table 2.
LPS induced changes in cytokine production in
shNEG and shTTP cell lines
In shNEG cell line the expression of 11 out of the 62
measured cytokines was changed following LPS treatment
(Table 3). With LPS treatment the expression of 9 cytokines
[GCSF, IL-6, LPS induced C-X-C chemokine (LIX), MCP-
1, MCP-5, MIP-2, MIP-3α, RANTES, and sTNF RII] and
the IL-12 p40 subunit increased. IL-12 p40 detects p40 sub-
unit in the active IL-12 p70 as well as all otherwise engaged
p40 subunits. On the contrary, the expression of CXCL16 in
LPS-treated shNEG cells decreased as compared to untreated
shNEG cells.
In shTTP cell line, the production of 10 cytokines (GCSF,
IL-6, IL-12, LIX, MCP-1, MCP-5, MIP-2, RANTES, sTNF
RII, and TNF-α) and IL-12 p40 subunit were increased fol-
lowing LPS treatment (Table 4).
Differences in LPS-induced cytokine expression in
shNEG and shTTP cell lines
The LPS-induced production of six cytokines (IL-6, IL-12,
IL-12 p40 subunit, MIP-2, MIP-3α, and TNF-α) was altered
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A B C D E F G H I J K L M N
1 POS POS POS POS Blank Ax1 BLC CD30 L CD30 T CD40 CRG-2 CTACK CXCL16 Eotaxin
2 NEG NEG NEG NEG Blank Ax1 BLC CD30 L CD30 T CD40 CRG-2 CTACK CXCL16 Eotaxin
3 Eotaxin-2
Fas
Ligand
Frac-
talkine
GCSF GM-CSF IFN-γ IGFBP-3 IGFBP-5 IGFBP-6 IL-1α IL-1β IL-2 IL-3 IL-3 Rβ
4 Eotaxin-2
Fas
Ligand
Frac-
talkine
GCSF GM-CSF IFN-γ IGFBP-3 IGFBP-5 IGFBP-6 IL-1α IL-1β IL-2 IL-3 IL-3 Rβ
5 IL-4 IL-5 IL-6 IL-9 IL-10 IL-12 p40 IL-12 IL-13 IL-17 KC Leptin R Leptin LIX L-Selectin
6 IL-4 IL-5 IL-6 IL-9 IL-10 IL-12 p40 IL-12 IL-13 IL-17 KC Leptin R Leptin LIX L-Selectin
7
Lympho-
tactin
MCP-1 MCP-5 M-CSF MIG MIP-1α MIP-1γ MIP-2 MIP-3β MIP-3α PF-4 P-Selectin RANTES SCF
8
Lympho-
tactin
MCP-1 MCP-5 M-CSF MIG MIP-1α MIP-1γ MIP-2 MIP-3β MIP-3α PF-4 P-Selectin RANTES SCF
9 SDF-1α TARC TCA-3 TECK TIMP-1 TNF-α sTNF RI sTNF RII TPO VCAM-1 VEGF Blank Blank Blank
10 SDF-1α TARC TCA-3 TECK TIMP-1 TNF-α sTNF RI sTNF RII TPO VCAM-1 VEGF Blank POS POS
(a)
Medium without cells
(b)
shNEG cells
without LPS
(c)
shNEG cells
with LPS (100 ng/mL)
(d)
shTTP cells
without LPS
(e)
shTTP cells
with LPS (100 ng/mL)
(f)
Figure 2: Cytokine antibody array. (a) A schematic diagram of the Mouse Cytokine Antibody Array III shows the locations of controls
and the duplicate spots of cytokines. (b)–(f) Images of the membranes treated with cell culture media from the following experiments: (b)
culture medium without cells, (c) shNEG cells, 49 h incubation, (d) shNEG cells, stimulated for 1 h with LPS (100 ng/mL) and incubated
thereafter for 48 h, (e) shTTP cells, 49 h incubation, (f) shTTP cells, stimulated for 1 h with LPS (100 ng/mL) and incubated thereafter for
48 h. Representative membranes of three with similar results are shown. POS = positive control, NEG = negative control.
Table 2: Cytokines secreted spontaneously by shNEG and shTTP
cell lines. Arbitrary units compared to positive controls (100) are
presented. Mean  SEM (n = 3).
Cytokine
Medium shNEG shTTP
without cells cell line cell line
CTACK 1.9 5.8 6.3
CXCL16 1.1 72.3 35.7
MIP-1α 2.9 82.3 117.5
MIP-1γ 1.8 118.4 128.8
TARC 2.5 41.3 28.1
 = P < .01,  = P < .05 as compared to the medium without cells.
in shTTP cells as compared to shNEG cells suggesting that
the expression of these six cytokines is regulated by TTP.
Cytokines IL-6, MIP-2, IL-12, and TNF-α were expressed
at higher levels in shTTP cell line than in shNEG cell line
(Figure 3). In contrast, MIP-3α and IL-12 p40 subunit were
expressed at lower levels in LPS-treated shTTP than in LPS-
treated shNEG cell lines (Figure 4).
DISCUSSION
The role of mRNA turnover in the regulation of inflamma-
tory gene expression has been recognized pathophysiologi-
cally and therapeutically important. TTP is one of the fac-
tors regulating mRNA decay. Here we report that TTP down-
regulation resulted in increased expression of TNF-α, MIP-2,
IL-6, and IL-12 in macrophages exposed to bacterial LPS. On
the other hand, the levels of MIP-3α were reduced in LPS-
treated TTP knock-down cells. The possible new targets for
TTP discovered in the present study are IL-12, MIP-2 (a ho-
mologue to human IL-8) and MIP-3α.
TTP is a regulator of the stability of some transiently ex-
pressed ARE-containing cytokine mRNAs. TTP has been re-
ported to down-regulate the expression of TNF-α, GM-CSF,
IL-2, IL-3, and IL-6 by destabilizing their mRNAs [9, 15–19].
In the present study, we established a cell line where TTP
was knocked down by expressing an shRNA against TTP, and
evaluated the levels of 62 cytokines secreted by the cells into
the culture medium by cytokine antibody array. Protein an-
tibody array has proved to be a useful tool to measure the
expression of multiple proteins in cells and tissues at the
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Table 3: Cytokines secreted by untreated and LPS- (100 ng/mL)
treated shNEG cells during 48 h incubation. Arbitrary units com-
pared to positive controls (100) are presented. Mean SEM (n = 3).
Cytokine
Medium shNEG cells
without cells Untreated LPS-treated
CXCL16 1.1 72.3 43.0
GCSF 2.3 3.3 21.4
IL-6 2.4 3.8 172.3
IL-12 p40 1.8 2.7 68.0
LIX 4.0 6.1 62.5
MCP-1 4.4 81.2 293.6
MCP-5 3.3 4.3 13.5
MIP-2 4.2 51.0 128.1
MIP-3α 3.9 5.3 18.1
RANTES 3.0 4.3 53.8
sTNF RII 3.9 11.4 20.6
 = P < .01,  = P < .05 for the diﬀerence between untreated and
LPS-treated shNEG cells.
Table 4: Cytokines secreted by untreated and LPS- (100 ng/mL)
treated shTTP cells during 48 h incubation. Arbitrary units com-
pared to positive controls (100) are presented. Mean SEM (n = 3).
Cytokine
Medium shTTP cells
without cells Untreated LPS-treated
GCSF 2.3 3.6 32.0
IL-6 2.4 3.5 258.0
IL-12 p40 1.8 2.9 41.6
IL-12 1.7 3.6 44.3
LIX 4.0 6.2 85.2
MCP-1 4.4 46.3 349.1
MCP-5 3.3 3.5 11.0
MIP-2 4.2 33.6 182.3
RANTES 3.0 4.6 57.5
sTNF RII 3.9 12.1 27.3
TNF-α 3.7 7.2 149.0
P < .01 for the diﬀerence between untreated and LPS-treated
shTTP cells.
same time. The results obtained are more significant than
when using cDNA microarrays as mRNAs are subjected to
post-transcriptional and post-translational processes and the
amount of mRNA may not correlate with protein expression
[25]. The advantage of protein array as compared to ELISA
is the simultaneous measurement of multiple proteins, but
it is regarded as a semiquantitative method. In the present
study, when TTP expression was induced by LPS, the TTP
knock-down cell line showed clearly reduced TTP protein
levels as compared to control cells. The reduction was func-
tionally significant as it resulted in a clear increase in TNF-α
production that is in line with the previous literature on the
eﬀects of TTP on TNF-α production [14, 24].
In experiments with TTP knock-out mice and cells de-
rived from them, TTP has been shown to mediate the
degradation of TNF-α and GM-CSF mRNAs [15, 16]. Both
transcripts contain AREs [26] and TTP binds to the non-
amer UUAUUUAUU in these structures with its zinc finger
domains [9, 27–30]. ARE-binding proteins such as TTP and
KSRP seem to accelerate the degradation of ARE-mRNAs
via the exosome pathway by recruiting the exosome to the
mRNA [31]. It has also been shown that TTP can promote
mRNA deadenylation by stimulating poly(A) ribonuclease
[32]. The N-terminal domain of TTP also associates with
mRNA decay enzymes involved in decapping, deadenylation,
and exonucleolytic decay [13]. In addition, TTP has been
proposed to direct certain mRNAs through stress granules
to processing bodies to be degraded there [11]. However, the
detailed mechanisms involved in the TTP-mediated mRNA
decay are not known.
IL-6 is another proinflammatory cytokine produced by
macrophages that is known to be regulated by TTP. It was
shown that IL-6 mRNA degradation was impaired in a
HT1080-derived mutant cell line. When the cells were then
stably transfected with TTP, the IL-6 mRNA decay restored
to the wild-type levels [19]. Here, we show that down-
regulation of TTP expression in activated macrophages re-
sulted in increased IL-6 production. These data suggest that
in wild-type cells IL-6 mRNA is destabilized by TTP.
In addition to TNF-α and IL-6 [9, 15, 19], TTP has been
reported to down-regulate the expression of GM-CSF, IL-
2, and IL-3 by destabilizing their mRNAs [16–18]. In the
present experiments, we were not able to detect these cy-
tokines in our macrophage cultures and could not draw any
conclusions on the eﬀects of TTP deficiency on those cy-
tokines.
IL-12 is a proinflammatory cytokine involved, for exam-
ple, in the pathogenesis of autoimmune diseases [33, 34]. IL-
12 is a heterodimer comprised of p35 and p40 subunits and
designated as IL-12 p70 [34]. The subunits are encoded by
two distinct genes and they need to be expressed simultane-
ously by the same cell to generate the biologically active het-
erodimer p70. Neither of the subunits is active on its own.
The p40 subunit can also form homodimers (IL-12 p80),
which act as endogenous IL-12 antagonists by binding to the
IL-12 receptor without inducing a cellular response. The p40
subunit is also a part of IL-23. Our results showed that IL-
12 was produced at higher levels in TTP-knock-down cells
than in control cells in response to LPS. The result suggests
a similar pattern of regulation of one or both of the subunits
of IL-12 as with TNF-α and IL-6 where TTP destabilizes the
mRNA and promotes its rapid degradation. To our knowl-
edge, this is the first time to report that the expression of IL-
12 is regulated by TTP.
In addition, we found a decrease in the expression of IL-
12 p40 subunit in LPS-treated shTTP cells as compared to
shNEG cells. In macrophages, the p40 subunit is secreted in
several-fold excess as compared to the p35–p40 heterodimer,
and the formation of active IL-12 (p35 and p40 heterodimer)
is regulated by the synthesis of p35 subunit [35]. The mRNA
of p35 (GenBank accession number NM 008351) contains
one copy of UUAUUUAUU nonamer which is the preferred
TTP binding site [30], where as none of those are found
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Figure 3: TTP down-regulation (shTTP cell line) enhanced the production of IL-6, IL-12, MIP-2, and TNF-α in response to LPS. Cytokine
antibody array membranes were incubated in medium control (M) or in media from cultures of TTP knock-down cells (shTTP cell line)
or control cells (shNEG cell line) after treatment with or without LPS (100 ng/mL). Values are arbitrary units compared to positive controls
(100) and are presented as mean  SEM (n = 3).  = P < .01,  = P < .05.
in p40 mRNA (GenBank accession number NM 008352).
Therefore we suggest that the target for TTP might be the
p35 subunit, which could be expressed at lower levels in the
LPS-treated shNEG cells than in shTTP cells. Further studies
are needed to understand the mechanisms how TTP regu-
lates IL-12 production.
A member of the CXC chemokine superfamily, MIP-2 (a
homologue to human IL-8), is a potent chemoattractant for
neutrophils [36]. In the present study, we found that MIP-2
production in response to LPS was higher in TTP knock-
down cells than in control cells. We are not aware of ear-
lier reports on the regulation of MIP-2 by TTP, and the re-
sults suggest a role for TTP as a destabilizer of MIP-2 mRNA.
The sequence of MIP-2 mRNA (GenBank accession number
NM 009140) contains three copies of the preferred nonamer
binding site of TTP (UUAUUUAUU), which further sup-
ports MIP-2 mRNA as a target of the destabilizing eﬀect of
TTP.
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Figure 4: TTP down-regulation (shTTP cell line) reduced the pro-
duction of MIP-3α and IL-12 p40 subunit in response to LPS. Cy-
tokine antibody array membranes were incubated in medium con-
trol (M) or in media from cell cultures of TTP knock-down cells
(shTTP cell line) or control cells (shNEG cell line) after treatment
with or without LPS (100 ng/mL). Values are arbitrary units com-
pared to positive controls (100) and are presented as mean   SEM
(n = 3).  = P < .01.
MIP-3α (synonyms: CC chemokine ligand 20, CCL20;
liver and activation-regulated chemokine, LARC; and
Exodus-1) is a chemokine which has a potential role in
rheumatoid arthritis [37]. In the present study, we found that
MIP-3α production in response to LPS was lower in cells
with reduced TTP expression than in control cells. That is
interesting, because TTP has been recognized as a factor that
down-regulates the expression of certain inflammatory genes
by destabilizing their mRNAs. MIP-3α seems to be an excep-
tion to that rule. Our result is supported by the fact thatMIP-
3α mRNA (GenBank accession number NM 016960) con-
tains no nonamer binding sites for TTP (UUAUUUAUU),
and therefore it is unlikely a direct target of TTP. Recently,
Fechir and coworkers reported that TTP was able to en-
hance human iNOS expression by stabilizing its mRNA in
cytokine-treated bronchial epithelial cell line [22]. TTP did
not bind to human iNOS mRNA but was shown to enhance
the half-life of iNOS mRNA by an indirect mechanism. TTP
was found to interact with KSRP and it was proposed to in-
hibit the degradation of iNOS mRNA and enhance iNOS ex-
pression by capturing KSRP [22]. In the present study, we
found that down-regulation of TTP resulted in reduction of
MIP-3α production. To our knowledge, this is the first report
to show that TTP regulates the production of MIP-3α. It re-
mains to be studied if TTP regulates MIP-3α expression in a
similar mechanism as has been reported for human iNOS.
The results presented here provide IL-12, MIP-2, and
MIP-3α as novel inflammatory cytokine targets for TTP-
regulatedmRNA decay. The data are implicated in the under-
standing of basic mechanisms of the inflammatory process
and in the development of novel anti-inflammatory drugs.
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